Your benchmark should match your business model.

Primary care is the gateway to the rest of the system, but reimbursement still favors procedures over time. Independent practices are weighing risk-bearing arrangements, telehealth retention, and team-based models against rising overhead and persistent staffing shortages.

• Value-based and capitated arrangements (ACO REACH, MA-aligned shared savings) continue to expand the share of primary care revenue tied to outcomes rather than volume.
• Behavioral health integration is moving from pilot to standard, partly driven by the CoCM (collaborative care) CPT codes and rising demand.
• Direct primary care and concierge models keep growing among small practices seeking insulation from payer churn.
• MA risk-adjustment scrutiny and payer downcoding are pushing practices to invest in coding accuracy and clinical documentation.
• Workforce: medical assistant turnover and panel-size pressure are the operational story of the year.

Primary care lives or dies on access and panel management. Our briefing focuses on third-next-available, no-show rate, and provider utilization — the levers that actually move revenue per provider.

GI is a procedure-driven specialty under steady fee-schedule pressure, with screening colonoscopy guidelines now reaching age 45 and a growing pipeline of biologics for IBD. Independent groups are consolidating into platforms while ASC ownership and ancillary lines (anesthesia, pathology, infusion) remain the durable margin story.

• USPSTF screening start age at 45 is still expanding the eligible pool, especially in commercially insured panels.
• Private equity-backed GI platforms continue to roll up regional groups; independence requires deliberate scale and governance choices.
• Anesthesia and pathology in-house captures, plus infusion suites for biologics, are where margin is being built or lost.
• Prior authorization burden for biologics keeps climbing — staffing the PA workflow is now an operational KPI in itself.
• AI-assisted polyp detection (CADe) is being adopted unevenly; ROI is real but requires endoscopist buy-in and case-mix.

Practices with procedure mix have a different chart of accounts. We benchmark contractual adjustments, ASC pull-through, and procedure scheduling efficiency separately from office visits.

Orthopedics has migrated meaningfully outpatient: total joints in ASCs are now standard, spine is following, and bundled payments continue to reshape episode economics. Implant cost capture, robotics utilization, and physical-therapy referral leakage are the levers that separate well-run groups from the rest.

• CMS site-neutral and ASC migration policies keep shifting more cases out of HOPDs; ASC ownership is the strategic question.
• Robotics adoption (Mako, ROSA, Velys) is broad but utilization quality is uneven; revenue-per-case and turnover time are the right metrics.
• Bundled payment and direct-to-employer arrangements reward groups that own the full episode from imaging through PT.
• Implant pricing, distributor consolidation, and supply chain tactics are an underrated margin lever.
• Workforce: OR techs and surgical RN supply remain the binding constraint on case volume in many markets.

Orthopedic practices typically run higher days-in-A/R and higher no-show rates. The benchmarks are calibrated to the specialty so you are not comparing yourself to the wrong baseline.

Heme/Onc economics live and die on drug margin, the 340B program, and access to clinical trials. Community oncology faces ongoing site-of-service pressure from health systems, while biosimilar adoption and the Inflation Reduction Act's drug pricing provisions are reshaping the buy-and-bill model in real time.

• IRA-driven Medicare price negotiation and Part B inflation rebates are starting to show up in real margin compression on selected drugs.
• Biosimilars (oncology supportive care and increasingly therapeutics) keep eroding ASP-based revenue but improve access.
• Community oncology consolidation (OneOncology, USON, AON) continues; staying independent requires real ancillary depth.
• Oral oncolytics shift revenue from medical to pharmacy benefits — in-house specialty pharmacy is a strategic question, not a tactical one.
• Clinical trial participation is a recruitment, branding, and revenue engine that smaller groups can punch above their weight on.

Heme/onc carries a different operating model — higher staff ratios, longer A/R, premium reimbursement, and tight quality compliance. The briefing scores all four together.

Optometry is part medical practice, part retail business, with optical capture rate and managed-vision plan participation defining most P&Ls. Myopia management and dry-eye programs are growing as ancillary medical lines while private equity continues to roll up larger MD/OD groups.

• Myopia management (atropine, ortho-K, soft myopia control lenses) is shifting pediatric optometry from refraction-only to an ongoing clinical service.
• Dry-eye dedicated clinics and IPL/RF devices have become a meaningful ancillary revenue line for many practices.
• Vision-plan economics (VSP, EyeMed) keep tightening — capture rate and lab strategy matter more than chair time.
• MD/OD integrated groups are scaling through PE platforms; pure-OD independents are sharpening differentiation through medical optometry.
• Telehealth refraction and online retailers are competitive pressure on the optical side, not the medical side.

Optometry has hybrid economics: insurance plus retail. The briefing reads both halves together — exam volume, dispensary capture, and conversion — alongside the standard KPIs.

Ophthalmology continues its long migration to ASCs and office-based procedure suites, with cataract still the volume engine and retina still the drug-spend engine. Premium IOLs, refractive cash channels, and disciplined ASC utilization are where well-run groups create real margin separation.

• ASC ownership and office-based surgery suites (intravitreal injections, YAG, MIGS in some states) keep moving cases out of HOPDs.
• Premium IOL conversion and refractive cash-pay channels remain the highest-leverage revenue lines for cataract-heavy groups.
• Retina drug economics (Eylea biosimilars, Vabysmo, faricimab dynamics) are reshaping the buy-and-bill side of the practice.
• PE consolidation continues; choices about platform partnership, MD/OD integration, and governance get more consequential each year.
• MIGS, gene therapy for retinal disease, and AI screening for diabetic retinopathy are the long-arc clinical/operational stories.

Ophthalmology shares optometry's retail dynamics with a surgical revenue layer. Our benchmarks isolate procedure throughput so growth and margin live on separate lines.

Urology is a procedure- and ancillary-heavy specialty where in-office labs, imaging, lithotripsy, and increasingly radiation/UroLift drive most of the margin. Independent groups are building large single-specialty platforms (LUGPA-style) to retain ancillaries that hospitals and payers keep pressuring.

• Large urology group platforms (LUGPA model) continue consolidating to preserve in-office ancillaries — pathology, imaging, and radiation oncology.
• Advanced prostate cancer drugs and in-office dispensing are a growing but compliance-heavy revenue line.
• Site-of-service pressure and prior auth on advanced imaging (mpMRI, PSMA PET) shape access and throughput.
• UroLift, Rezum, and other in-office BPH procedures are shifting cases out of the OR and into the clinic.
• Workforce: a well-documented urologist shortage makes APP leverage and retention a core operational lever.

Urology economics live in the ancillaries — in-office labs, imaging, lithotripsy, and in-office BPH procedures. The briefing scores procedure throughput and ancillary capture alongside the standard revenue-cycle KPIs.

Plastic surgery straddles two economies: insured reconstructive work with conventional revenue-cycle dynamics, and an elective cash-pay aesthetic practice that behaves more like a luxury retail business. The best-run practices manage them on separate ledgers, with marketing CAC, consult-to-conversion, and financing mix as the aesthetic-side KPIs.

• Cash-pay aesthetics keep growing; consult-to-surgery conversion and patient financing (CareCredit, Cherry) are the real revenue levers.
• Med-spa adjacencies (injectables, devices, skincare) provide recurring revenue that smooths surgical seasonality.
• Digital marketing and reputation management now function as a primary patient-acquisition channel, with measurable CAC.
• GLP-1-driven weight loss is expanding demand for body-contouring and skin-removal procedures.
• Reconstructive payer mix and prior authorization remain the operational drag on the insured side of the practice.

Plastic surgery runs insured reconstructive work next to a cash-pay aesthetic business. We benchmark them separately so consult-to-conversion and financing mix don't get buried under conventional revenue-cycle metrics.

Radiology economics center on read volume, modality mix, and the relentless pressure of the professional-fee conversion factor. Independent imaging centers and radiology groups are weighing teleradiology leverage, subspecialty reads, and the shift of imaging away from hospital outpatient departments toward lower-cost freestanding sites.

• Site-neutral and payer steerage continue to move imaging volume to freestanding centers from HOPDs.
• Teleradiology and night/subspecialty coverage models reshape staffing economics and read-quality benchmarks.
• AI triage and workflow tools are being adopted for efficiency and prioritization, with ROI tied to throughput, not headcount cuts.
• Radiologist supply shortages and burnout are pushing RVU-per-FTE and turnaround time to the center of operations.
• No Surprises Act and out-of-network dynamics affect collections for hospital-based and contracted reads.

Radiology margin turns on read volume, modality mix, and turnaround. The briefing tracks throughput and collections together so site-of-service shifts and out-of-network dynamics stay visible.

Cardiology is a high-ancillary specialty — nuclear, echo, cath, and EP — where the long arc has been from hospital employment back toward independence as payers and CMS revalue office-based and ASC-based cardiovascular procedures. Imaging accreditation, device clinic throughput, and cardiovascular ASC strategy define the margin.

• CMS has been rebuilding office- and ASC-based cardiovascular procedure payment, reopening the case for independence and de-novo cardiovascular ASCs.
• In-office ancillaries (nuclear, echo, vascular, device/remote-monitoring clinics) remain the core margin engine.
• Remote patient monitoring and CIED remote interrogation are recurring-revenue lines with their own staffing and compliance needs.
• Value-based cardiology and bundled cardiac episodes are expanding among larger groups.
• Private equity and large cardiovascular platforms (US Heart & Vascular-style) are actively consolidating independent groups.

Cardiology carries nuclear, echo, cath, and device-clinic ancillaries. We isolate procedure and ancillary lines so the move back toward independence shows up as margin, not noise.

Interventional pain management is procedure-driven and unusually exposed to payer policy — LCDs, prior authorization, and periodic coverage changes for injections and neuromodulation can reset the revenue base quickly. Practices balance interventional procedures, medication management compliance, and ASC strategy under heavy regulatory scrutiny.

• Payer medical-policy changes and prior authorization for epidural and facet procedures directly reshape procedure volume and revenue.
• Neuromodulation (SCS, peripheral nerve stimulation) is a growing, capital- and authorization-intensive line.
• Controlled-substance compliance, PDMP, and DEA scrutiny make documentation and toxicology workflows operational necessities.
• ASC and office-based procedure migration affects facility revenue and site-of-service strategy.
• Multidisciplinary models (behavioral health, PT, regenerative offerings) are differentiators where reimbursement allows.

Interventional pain is unusually exposed to payer policy and prior authorization. The briefing watches procedure volume, denial rate, and compliance workflows so coverage changes don't reset the revenue base unseen.